Context and Objective: Pain-related immobility because of insufficiency fractures may result in serious complications and a high mortality rate in senile patients with preexisting comorbidities. This study aimed to evaluate the efficacy of teriparatide in patients with sacral insufficiency fractures.
S acral insufficiency fractures occur as a result of minor injury and are common in elderly patients with osteoporosis. In accordance with the increase in the aging population, the incidence of these fractures is increasing. Pain-related immobility because of insufficiency fractures may result in serious complications and a high mortality rate in elderly patients with preexisting comorbidities.
The primary strategy in the treatment of sacral insufficiency fractures is pain management, patient mobilization, and the prevention of problems associated with comorbid conditions (1) . Only unusual cases require treatment with internal or external fixation (2) .
Outcomes of sacroplasty and other surgical treatments for sacral insufficiency fractures have been reported. Although these surgical interventions show good clinical outcomes at the minimum 1-year followup, they may cause serious problems such as nerve palsy, infection, and procedure-related complications (3) (4) (5) . Teriparatide treatment yields favorable results for the healing of other insufficiency fractures, atypical fractures, and nonunions (6) (7) (8) (9) (10) (11) . Since 2007, we have been using teriparatide for treating osteoporosis, complicated fractures, nonunions, and sacral insufficiency fractures in elderly patients.
The purpose of this case-control study was to assess functional outcomes including change in pain severity during follow-up, bony union times, and complications related to teriparatide in patients with sacral insufficiency fractures.
Materials and Methods
This study was approved by the institutional review board of the Chung-Ang University Hospital, and the requirement for informed consent was waived. Of the 55 consecutive patients whose sacral insufficiency fracture was confirmed using magnetic resonance imaging (MRI) or bone scan in our hospital between January 2009 and December 2014, 41 patients who were older than 50 years, had no signs of infection such as local heat, redness, or swelling, had not received radiation therapy, and whose medical progress could be followed up for more than 1 year were included in the study. These patients were divided into 2 groups, a teriparatide treatment group (group I) of 21 patients who received treatment with teriparatide, and a control group (group II) of 20 patients who refused teriparatide treatment (Fig. 1) .
Demographic data, including age, sex, height, weight, body mass index, medical comorbidities on the basis of the modified Charlson comorbidity index (12) , and history of other previous osteoporotic fractures appear in Table 1 .
Diagnosis of sacral insufficiency fracture
Patients were admitted to the hospital with severe acute pain in the low back area. If sacral insufficiency fractures were suspected, an initial radiograph was taken and then a bone scan and/or MRI scan (Fig. 2) was routinely performed to confirm the diagnosis. For patients with sacral insufficiency fractures, the plain pelvic radiography was repeated and the functional progression was assessed every 4 weeks.
Patients were concurrently screened for osteoporosis using dual-energy absorptiometry (Lunar Prodigy; GE Healthcare, Little Chalfont, UK). According to a World Health Organization study group, the diagnosis of osteoporosis is based on T-score thresholds. T scores at or below 22.5 and a history of previous osteoporotic fracture are considered severe osteoporosis (13) . Routine laboratory examinations, including white blood cell counts, C-reactive protein, and erythrocyte sedimentation rate, and additional bone-turnover markers, such as serum alkaline phosphatase, parathyroid hormone (PTH), 
Teriparatide group and control group
The teriparatide treatment group (group I) underwent once-daily subcutaneous treatment with 20 mg of teriparatide to evaluate its effect on the time required for radiographic and clinical fracture healing. The 21 patients in the treatment group received 20 mg of PTH 1-34 (Forteo®; Eli Lilly, Indianapolis, IN) within 2 days after admission to the hospital. Twenty patients who did not receive teriparatide treatment (group II) served as the control group. All patients in the teriparatide treatment group received teriparatide for a minimum of 3 months (range, 3 to 11 months). All patients received daily supplementation consisting of 1000 mg of calcium and 800 IU of vitamin D3 for the entire study period.
Patients with breakthrough pain in either group were prescribed medication for pain control, and the frequency and duration of breakthrough pain were recorded during the study.
Assessment of clinical fracture healing and functional outcome
Functional outcome was defined as a reduction in pain and an improvement in mobility and was assessed using a numeric visual analog scale (VAS) for pain (with 0 representing no pain and 10 representing the greatest imaginable pain) on the date of admission (at least 2 days after the fracture) and at 1, 4, 8, and 16 weeks. VAS scores were classified as mild (0 to 3), moderate (4 to 6), or severe (7 to 10) pain according to the World Health Organization system (14) . Frequency and duration of pain medication use were compared between the 2 groups.
Regarding the time to mobilization, we measured the period of time until patients started walking without walking aids for the first time.
Assessment of fracture healing by imaging studies
Fracture healing was assessed by x-ray on the day of admission (at least 2 days after the fracture) and at 1, 4, 8, 12, and 16 weeks, and regularly thereafter until evidence of fracture healing (defined as cortical bridging) was confirmed. The percentage of fractures that had healed at 8 weeks was the primary end point of interest. X-rays were assessed independently by 2 orthopedic surgeons. All assessments were blinded.
Statistical analysis
Data are expressed as means and standard deviations or as numbers and percentages. The significance level (alpha) was set to 0.05. The x 2 test was used to compare the groups in terms of categorical variables. The Mann-Whitney U test was used to compare the groups in terms of continuous and ordinal variables.
Results
Pain in all patients had subsided by the last follow-up. Group I showed earlier improvement in comparison with group II in terms of functional outcome (as assessed by both the VAS score and time to mobilization). From the date of admission to 4 weeks, the mean VAS score improved from 6.9 to 3.8 in group I and from 6.5 to 5.1 in group II. At 4 weeks, the VAS scores of the 2 groups differed significantly (P = 0.002).
Serial assessment of pain was performed using a VAS grading system from the date of admission to 12 weeks. One week after starting the injections, the proportions of mild pain in groups I and II were 42.9% and 15%, respectively (P = 0.114). Four weeks after beginning injections, the proportions of mild pain in groups I and II were 42.9% and 15%, respectively (P = 0.114). At 8 weeks postmedication, the proportions of mild pain in groups I and II were 38.1% and 15%, respectively (P = 0.095). At 12 weeks postmedication, the proportions of mild pain in groups I and II were 100% and 50%, respectively (P , 0.001; Fig. 3 ).
Among the patients who reported analgesic medication use at 3 months, 28.6% (6 of 21) of group I and 55.0% (11 of 20) of group II patients took analgesic medications (P = 0.086), and the rest of the patients reported not taking analgesic medications. At 6 months, 14.3% (3 of 21) of group I and 25.0% (5 of 20) of group II patients were still using analgesic medications (P = 0.387).
The mean time to mobilization was 1.2 6 0.4 weeks in group I, compared with 2.0 6 0.3 weeks in group II (P , 0.001; Table 2 ).
The median time from fracture to the first sign of callus of the sacral insufficiency fracture, as verified by x-ray, was 10.6 weeks in the treatment group compared with 13.6 weeks in the control group (P , 0.001). At week 8, which was the primary end point, all fractures in the treatment group and 2 fractures in the control group had healed [healing rate, 100% (95% confidence interval, 87.5% to 100.0%) compared with 10% (95% confidence interval, 2.5% to 14.7%)].
Discussion
Sacral insufficiency fractures in the elderly are associated with delayed fracture healing as a result of impaired bone quality, causing long-term pain and long-term immobilization, which lead to greater morbidity and mortality. To date, several methods for treatment of sacral insufficiency fractures have been introduced (3) (4) (5) 15) (Table 3) .
This article reports on the effects of teriparatide treatment of sacral insufficiency fractures in elderly patients. Our results indicate earlier subsidence of pain and earlier mobilization occur after teriparatide treatment.
Sacroplasty has recently been considered 1 of the options to treat intractable pain associated with sacral insufficiency fractures. Many authors have reported good results with sacroplasty (3-5, 15). Gupta et al. (5) performed sacroplasty in 53 elderly patients with sacral insufficiency fractures and reported pain reduction and functional outcomes at a mean of 27 days after sacroplasty. However, it was difficult to make a direct comparison with patients in the control group, who were treated with a conservative method, because these studies were case reports or case series. In addition, sacroplasty has a severe shortcoming in that cement-related complications may occur, and a physiologic bone healing pathway is not followed. However, our controlled study using teriparatide showed outcomes comparable with studies involving sacroplasty. From week 0 to week 8, the mean VAS score improved from 7.6 to 3.2 in the treatment group and from 7.7 to 6.5 in the control group. The mean time to mobilization was 1.1 6 0.4 weeks in the teriparatide treatment group compared with 4.0 6 0.3 weeks in the control group (P , 0.001). Our results indicate that teriparatide treatment in patients with sacral insufficiency fracture resulted in earlier subsidence of pain and mobilization compared with the control group. In addition, patients with sacral insufficiency fracture often have concomitant osteoporosis, for which teriparatide can be used as an anabolic agent.
At the 4-week follow-up, the pain score in the teriparatide treatment group was significantly lower than that in the control group. Teriparatide injection therapy rapidly and significantly reduced back pain in patients with vertebral fractures. Genant et al. (16) reported that press.endocrine.org/journal/jcemthe risk of back pain was reduced by 31% for moderate or severe back pain and by 57% for severe back pain after using teriparatide. A meta-analysis involving 5 clinical trials reported that patients in the pooled teriparatide group had a reduced relative risk that ranged from 0.44 to 0.60 for all types of back pain. Although there are no data suggesting an analgesic effect of teriparatide, teriparatide has been shown in animal models to accelerate fracture healing and may heal and stabilize preexisting fractures or microdamage in patients with advanced osteoporosis (17) (18) (19) . The effectiveness of teriparatide for healing fractures has been reported by several studies in delayed or nonunion, atypical femoral fractures, pelvic bone fractures, and other fractures (6, 10, 20, 21) . Several studies have suggested that bone healing in humans is enhanced by PTH treatment (22) (23) (24) . Chiang et al. (25) demonstrated that teriparatide use was associated with increased bone remodeling in patients with atypical femoral fractures after surgical procedures. Peichl et al. (11) performed a case-control study in patients with pelvic bone fracture using PTH treatment (21 patients) and conservative treatment (44 patients). They reported that the mean time to fracture healing was 7.8 weeks in the treatment group compared with 12.6 weeks in the control group (P , 0.001). This study is consistent with previous reports. We found that the mean time to fracture healing was 7.4 weeks in the treatment group compared with 13.6 weeks in the control group. Although the exact mechanisms by which PTH stimulates bone healing in various animal models are unclear, PTH stimulates hard-callus formation and increases the strength of the fracture site (17, 26) .
This study has several limitations. First, this was a retrospective case-control study, and thus, selection bias might have been introduced when choosing members of the control group. In our study, a protocol for referral to MRI or computed tomography could not be applied to all patients with hip pain after trauma who had normal or equivocal findings on conventional radiographs during the study period. Second, this study involved insufficient assessment of the union at the fracture site. Fracture healing was assessed using standard radiography. However, most fracture healing occurs in the trabecular area of the sacrum. Formation of bony callus in sacral insufficiency fractures is not typically visible. Therefore, the exact time of fracture healing was difficult to determine in most patients. Finally, the patient response with respect to the VAS and time to mobilization were nonuniform; although documentation of these scores became routine during the study period, their validity in a retrospective study is insufficient. Despite these limitations, this study aimed to evaluate the efficacy of teriparatide in patients with sacral insufficiency fractures.
In conclusion, in patients in this population (senile patients with preexisting comorbidities) who have sacral insufficiency fractures, teriparatide treatment may achieve earlier pain reduction and mobilization, with reduced healing time and reduced risk of complications. 
